NCT01256073 2014-02-28A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid LeukaemiaInnate PharmaPhase 1 Completed21 enrolled